PACTR202007553348930Not yet recruiting未知
Parasite Clearance of Two Commonly Administered Artemisinin-Based Combination Therapies in Under-Five Children With Uncomplicated Malaria at Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife.
Ahmed Abdulakeem0 sites122 target enrollmentStarted: June 15, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 122
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 2 Year(s) to 5 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •(i)All patients between the age of 6 month and 59 months with signs and symptoms of acute uncomplicated malaria.
- •(ii)Axillary temperature =37.5 ºC or history of fever during the past 24 hr.
- •(iii)Ability to swallow oral medication.
- •(iv)Microscopically confirmed asexual forms of P. falciparum with parasite density count of between 2000 and 200 000 parasites / µl.
- •(v)Willingness of the parent/guardian to comply with protocol as regards the study visit schedule.
Exclusion Criteria
- •(i)Those having symptoms and signs of severe falciparum malaria.
- •(ii)A febrile condition due to diseases other than malaria e.g. measles, acute lower respiratory tract infection.
- •(iii)Patients having severe malnutrition.
- •(iv) Patients with sickle cell anaemia.
- •(v)History of use of medication such as erythromycin, azithromycin, clindamycin and Septrin that might interfere with antimalarial pharmacokinetics.
- •(vi)History of hypersensitivity to any of the study drugs will be excluded from the study.
Investigators
Similar Trials
Unknown
Not Applicable
Comparing drug-regimens for clearing parasites in Phase IIb trial designs prior to PCR monitoring for Plasmodium falciparum infectioMalariaPACTR201309000625311KEMRI Wellcome Trust Research Programme90
Completed
Not Applicable
Efficacy and parasite clearance time with artemether-lumefantrine for uncomplicated falciparum malaria in children of Nchelenge District, ZambiaMalariaPACTR201905783261453Macha Research Trust100
Not yet recruiting
Phase 4
Assessment of combined antiparasitic drugs praziquantel and albendazole versus albendazole alone in the treatment of active parenchymal neurocysticercosis in Tanzania and Zambia.NeurocysticercosisPACTR202402822223203REvolution Worldwide S.r.l. Impresa Sociale300
Recruiting
Phase 4
A study to compare different materials to stop dental decay.CTRI/2020/01/022794DR ZADC
Not yet recruiting
Phase 2
clinical and microbiological efficacy of arimedadi oilCTRI/2021/05/033384mme kulsum